Peptide · Fact sheet

Semax

Also known as Semax heptapeptide · ACTH(4-7)-Pro-Gly-Pro

Semax is a synthetic seven-amino-acid peptide studied mainly in Russian stroke and neuroscience research. It is not FDA approved for stroke, cognition, focus, memory, mood, or any other use.

Not FDA approvedLimited or unclear evidence

What is Semax?

Semax combines a fragment related to adrenocorticotropic hormone with a Pro-Gly-Pro sequence and is designed to have neuroactive effects without the full hormone's endocrine activity.

Most modern mechanistic claims come from animal, cell, or gene-expression studies rather than confirmatory human outcome trials.

Benefits & claims

It is marketed online as a nootropic or neuroprotective peptide for memory, attention, stress, and recovery after neurologic injury.

The human literature is dominated by older, small studies with limited reporting, while FDA identifies route-specific safety and peptide-quality uncertainties.

What the evidence supports

  • A small 1997 controlled study in acute ischemic stroke reported signals in neurologic recovery, but its design and reporting do not support broad clinical conclusions.
  • Preclinical studies suggest effects on neurotrophic, inflammatory, and gene-expression pathways; those are hypotheses, not proof of better cognition in people.
Research areas
  • Ischemic stroke recovery
  • Neuroprotection in animal models
  • Cognition, attention, and memory claims
  • Stress-response and gene-expression mechanisms
  • Neurologic recovery and neuroprotection
  • Cognitive and stress-related outcomes

Dosage & frequency

No established human regimen

Small neurologic studies do not establish an FDA-approved Semax regimen or a general cognitive-enhancement schedule.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Intranasal research and other claimed delivery routes cannot be assumed equivalent.

Interactions & precautions

  • Reviewed neurologic studies do not establish compatibility with every CNS-active medicine or other intranasal peptide.

What is still unresolved

  • Replicated clinical efficacy, optimal exposure, repeated-use safety, and interactions remain uncertain.

Side effects & risks

  • FDA identifies possible immune reactions, aggregation, peptide impurities, and limited route-specific human safety information.
  • There is no mature adverse-event database for repeated use in healthy people or people with neurologic disease.
  • Unapproved products add uncertainty about identity, purity, strength, sterility, and labeling.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

Small older human stroke studies exist, but they do not establish a reliable modern evidence base for cognitive enhancement or routine neurologic treatment. Much of the supporting literature is preclinical.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Energy: reported experiences

Negative account · personal report

Headache, nausea and poorer concentration

An author reported fatigue, anxiety and poor focus, followed by a severe headache and nausea. Their update described feeling better three days after stopping.

Reported use in this account

Product
Product labeled Semax nasal spray
Amount
500 mcg at a time, after the author's correction
Frequency
Not specified clearly
Route
Nasal spray
Duration
Four days before headache; improvement reported after three days off

The author also reported ADHD and withholding their usual medication during this experience. Product identity and symptom causation were not verified.

Read the original account
No noticeable effect · personal report

No noticeable change after a week

An author described no improvement in focus, motivation, energy or mood during their first week, despite expecting a strong effect.

Reported use in this account

Product
Product labeled Semax nasal spray
Amount
400 mcg initially, later 800 mcg, as reported
Frequency
Not specified clearly
Route
Nasal spray
Duration
One week at the time of the post

This short account has no objective testing or verified product analysis. It does not establish long-term effects.

Read the original account

Approval status

Semax has no FDA-approved drug product or use. FDA's current compounding safety page identifies potential immune and impurity risks and limited safety information for proposed routes.

No active FDA approval path identified

Semax is not FDA approved, and the cited evidence is older, limited, or preclinical. Current references do not show a U.S. approval program.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether Semax improves cognition, memory, attention, or function in well-controlled modern trials
  • Short- and long-term safety across populations
  • Whether older stroke findings can be replicated with current trial methods and standard care
  • The identity and quality of products marketed under the name

Summary

Semax is unapproved. Its small, older human studies do not establish reliable cognitive-enhancement benefits.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

  2. pubmedControlled clinical study of Semax in ischemic stroke

    Small older human study with important design, reporting, and generalizability limits.

  3. pubmedPreclinical Semax gene-expression study

    Rat ischemia study supporting mechanistic hypotheses, not human cognitive benefit.

  4. fdaFDA: understanding the risks of compounded drugs

    FDA overview explaining that compounded drugs are not reviewed before marketing for safety, effectiveness, or quality.

How we assess sources · Suggest a correction